Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/17/2025

Lactic Acidosis Risk Comparison

Introduction to Lactic Acidosis

  • The American Journal of Kidney Diseases recommends that patients with renal impairment (eGFR <30 ml/min/1.73 m²) should avoid metformin due to the increased risk of lactic acidosis 3, 4
  • The Lancet Diabetes and Endocrinology states that metformin can cause lactic acidosis, especially in patients with renal impairment or those undergoing major surgery, with a reported incidence rate of less than 1 per 100,000 patient-years 1
  • Diabetes Care suggests that the risk of metformin-induced lactic acidosis is higher in patients with heart failure, hypoxemia, sepsis, or other conditions that may increase lactate production 5, 6

Patient Selection

  • The American Journal of Kidney Diseases advises that metformin is contraindicated in patients with eGFR <30 ml/min/1.73 m² due to the high risk of lactic acidosis 3, 4
  • Praxis Medical Insights recommends considering imeglimin as a safer alternative to metformin in patients with renal impairment or acute diseases, although long-term clinical experience is still limited 2
  • The Lancet Diabetes and Endocrinology notes that imeglimin may have a lower risk of lactic acidosis compared to metformin, especially in patients with renal impairment or those undergoing major surgery 1

REFERENCES

3

management of diabetes and hyperglycaemia in the hospital. [LINK]

The Lancet Diabetes and Endocrinology, 2021

6

Lactic Acidosis Risk in Diabetes Treatment [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025